Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment

被引:25
作者
Belimezi, Maria M.
Papanastassiou, Danai
Merkouri, Efrossini
Baxevanis, Constantin N.
Mamalaki, Avgi
机构
[1] Hellenic Pasteur Inst, Dept Biochem, Lab Mol Biol & Immunobiotechnol, Athens 11521, Greece
[2] St Savas Canc Hosp, Canc Immunol & Immunotherapy Ctr, Athens 11522, Greece
关键词
Her2/neu; human Fab; phage display; cancer immunotherapy;
D O I
10.1007/s00262-005-0100-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The Her2/neu oncogene is overexpressed in various human cancers of epithelial origin and is associated with increased metastatic potential and poor prognosis. Blocking the Her2/neu signalling has been the focus of most therapeutic approaches. In this paper, the Her2/neu extracellular domain expressed in soluble form in yeast Pichia pastoris was used in order to isolate a fully human Fab fragment from a combinatorial Fab phage display library, derived from invaded lymph nodes of a breast cancer patient. The isolated fully human Fab63 binds specifically the native Her2/neu receptor and competes with Herceptin for binding to soluble Her2/neu receptor. In Her2/neu overexpressing cancer cells, Fab63 is rapidly internalized and has significant antiproliferative effects, where ligand-independent mechanisms dominate signal induction. Moreover, in the presence of the ligand heregulin, growth inhibition was also detected by Fab63. The human Fab63 is a non-immunogenic agent with unique properties that can be applied in diagnosis and cancer therapy, with great potential for further manipulation towards the generation of an effective anticancer molecule.
引用
收藏
页码:1091 / 1099
页数:9
相关论文
共 43 条
[1]
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].
Agus, DB ;
Gordon, MS ;
Taylor, C ;
Natale, RB ;
Karlan, B ;
Mendelson, DS ;
Press, MF ;
Allison, DE ;
Sliwkowski, MX ;
Lieberman, G ;
Kelsey, SM ;
Fyfe, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543
[2]
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[3]
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin [J].
Austin, CD ;
De Mazière, AM ;
Pisacane, PI ;
van Dijk, SM ;
Eigenbrot, C ;
Sliwkowski, MX ;
Klumperman, J ;
Scheller, RH .
MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (12) :5268-5282
[4]
ASSEMBLY OF COMBINATORIAL ANTIBODY LIBRARIES ON PHAGE SURFACES - THE GENE-III SITE [J].
BARBAS, CF ;
KANG, AS ;
LERNER, RA ;
BENKOVIC, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (18) :7978-7982
[5]
BARBAS CF, 1994, MONOCLONAL ANTIBODIE
[6]
Mechanism of action of anti-HER2 monoclonal antibodies [J].
Baselga, J ;
Albanell, J .
ANNALS OF ONCOLOGY, 2001, 12 :35-41
[7]
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy [J].
Baxevanis, CN ;
Sotiropoulou, PA ;
Sotiriadou, NN ;
Papamichail, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) :166-175
[8]
[9]
HUMAN-ANTIBODIES FROM COMBINATORIAL LIBRARIES [J].
BURTON, DR ;
BARBAS, CF .
ADVANCES IN IMMUNOLOGY, VOL 57, 1994, 57 :191-280
[10]
Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129